Psychiatric comorbidity and additional abuse of drugs in maintenance treatment with l- and d,l-methadone

References

• American Psychiatic Association. 1998. Diagnostic and statistical manual for psychiatric disorders (DSM-IV) German Version, H Saß, Wittchen, HU, Zaudig, M, Göttingen, Hogrefe
   Google Scholar
• Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Task Force on Unipolar Depressive Disorders WFSBP, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 2007; 8(2)67–104
   PubMed Web of Science ®Google Scholar
• Bonsack C, Camus D, Kaufmann N, Aubert AC, Besson J, Baumann P, et al. Prevalence of substance use in a Swiss psychiatric hospital: Interview reports and urine screening. Addict Behav 2006; 31(7)1252–1258
   PubMed Web of Science ®Google Scholar
• Brooner RK, King VL, Kidorf M, Schmidt CW, Jr, Bigelow GE. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 1997; 54(1)71–80
   PubMed Web of Science ®Google Scholar
• Codd EE, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgetics: structural determinants and role in antinociception. J Pharmacol Exp Ther 1995; 274: 1263–1270
   PubMed Web of Science ®Google Scholar
• Darke S, Swift W, Hall W. Prevalence, severity and correlates of psychological morbidity among methadone maintenance clients. Addiction 1994; 89(2)211–217
   PubMed Web of Science ®Google Scholar
• De Vos JW, Ufkes JGR, Kaplan Cd, Tursch M, Krause JKA, van Wilgenburg H, et al. l-Methadone and d,l-methadone in methadone maintenance treatment: A comparison of therapeutic effectiveness and plasma concentrations. Eur Addict Res 1998; 3(4)134–141
   Google Scholar
• Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res (Suppl) 1999; 35: 93–100
   PubMed Web of Science ®Google Scholar
• Eap CB, Finkbeiner T, Gastpar M, Scherbaum N, Powell K, Baumann P. Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. Eur J Clin Pharmacol 1996; 50: 385–389
   PubMed Web of Science ®Google Scholar
• Eap CB, Borquin M, Martin J, Spagnoli J, Livoti S, Powell K, et al. Plasma concentrations of the enantiomeres of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend 2000; 61(1)47–54
   PubMed Web of Science ®Google Scholar
• Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 14: 1153–1193
   Google Scholar
• Eap CB, Felder C, Golay KP, Uehlinger C. Increase of oral methadone dose in methadone injecting patients: a pilot study. J Addict Dis 2003; 22(3)7–17
   PubMed Web of Science ®Google Scholar
• Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone – metabolism, pharmacokinetics and interactions. Pharmacol Res 2004; 50(6)551–559
   PubMed Web of Science ®Google Scholar
• Gelkopf M, Weizman T, Melamad Y, Adelson M, Bleich A. Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic. Isr J Psychiatry Relat Sci 2006; 43(2)126–136
   PubMed Web of Science ®Google Scholar
• Gsellhofer B, Fahrner EM. European Addiction Severity Index (EuropASI). Manual für Training und Durchführung von Interviews mit dem EuropASI. Institut für Therapieforschung, Munich 1994
   Google Scholar
• Havassi BE, Alvidrez J, Owen KK. Comparison of patients with comorbid psychiatric and substance use disorders: implications for treatment and service delivery. Am J Psychiatry 2004; 161(1)139–145
   PubMedGoogle Scholar
• Havemann-Reinecke U, Küfner H, Schneider U, Günthner A, Schalast N, Vollmer HC. AWMF-Leitlinien: Postakutbehandlung bei Störungen durch Opioide. Sucht 2004; 50(4)226–257
   Google Scholar
• Hendriks VM. Psychiatric disorders in a Dutch addict population: Rates and correlates of DSM-III diagnosis. J Consult Clin Psychol 1990; 58: 158–165
   PubMed Web of Science ®Google Scholar
• Hesse M. The Beck depression inventory in patients undergoing opiate antagonist maintenance treatment. Br J Clin Psychol 2006; 45: 417–425
   PubMed Web of Science ®Google Scholar
• Hu HM, Kline A, Huang FY, Ziedonis DM. Detection of co-occurring mental illness among adult patients in the New Jersey substance abuse treatment systems. Am J Public Health 2006; 96(10)1785–1793
   PubMed Web of Science ®Google Scholar
• Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994; 51: 8–19
   PubMed Web of Science ®Google Scholar
• Khantzian EJ, Treece C. DSM-III psychiatric diagnosis of narcotic addicts. Recent findings. Arch Gen Psychiatry 1985; 42(11)1067–1071
   PubMed Web of Science ®Google Scholar
• Krausz M, Verthein U, Degkwitz P. Prävalenz psychischer Störungen bei Opiatabhängigen mit Kontakt zum Drogenhilfesystem. Nervenarzt 1998; 69: 557–567
   PubMedGoogle Scholar
• Kuntze MF, Ladewig D, Stohler R. Prevalence rates of psychiatric and substance use comorbidity in an outpatient methadone maintenance clinic. Sucht 1998; 44(2)96–103
   Google Scholar
• Leavitt SB, Shinderman M, Maxwell S, Eap CB, Paris P. When “enough” is not enough: new perspectives on optimal methadone maintenance dose. Mt Sinai J Med 2000; 67: 404–411
   PubMed Web of Science ®Google Scholar
• Margraf J. Diagnostisches Kurzinterview bei psychischen Störungen: Mini-DIPS. Springer, Berlin 1994
   Google Scholar
• Maremmani I, Zolesi O, Aglietti M, Marini G, Tagliamonte A, Shinderman M, et al. Methadone dose and retention during treatment of heroin addicts with axis I psychiatric comorbidity. J Addict Dis 2000; 19(2)29–41
   PubMed Web of Science ®Google Scholar
• Maremmanin I, Pani PP, Pacini M, Perugi G. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J Substance Abuse Treat 2007; 33(1)91–98
   PubMedGoogle Scholar
• Mason BJ, Kocsis JH, Melia D, Khuri ET, Sweeney J, Wells A, et al. Psychiatric comorbidity in methadone maintained patients. J Addict Dis 1998; 17(3)75–89
   PubMed Web of Science ®Google Scholar
• Millson P, Challacombe L, Villeneuve PJ, Strike CJ, Fischer B, Myers T, et al. Determinants of health-related quality of life of opiate users at entry to low threshold methadone programs. Eur Addict Res 2006; 12(2)74–82
   PubMedGoogle Scholar
• Möller HJ. Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychosis: conceptual and treatment issues. World J Biol Psychiatry 2005; 6(4)247–263
   PubMed Web of Science ®Google Scholar
• Peles E, Schreiber S, Namovsky Y, Adelson M. Depression in methadone maintenance treatment patients: rate and risk factors. J Affect Disord 2007; 99(1–3)213–220
   PubMedGoogle Scholar
• Phillips J, Carpenter KM, Nunes EV. Suicide risk in depressed methadone-maintained patients: associations with clinical and demographic characteristics. Am J Addict 2004; 13(4)327–332
   PubMed Web of Science ®Google Scholar
• Raffa JD, Grebely J, Tossonian H, Wong T, Viljoen M, Khara M, et al. The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program. Drug Alcohol Depend 2007; 89(2–3)306–309
   PubMed Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. J Am Med Assoc 1990; 264: 2511–2518
   PubMed Web of Science ®Google Scholar
• Rosenblum A, Parrino M, Schnoll SH, Fong C, Maxwell C, Cleland CM, et al. Prescription opioid abuse among enrolees into methadone maintenance treatment. Drug Alcohol Depend 2007; 90(1)64–71
   PubMed Web of Science ®Google Scholar
• Rupprecht R, Eser D, Zwansger P, Möller HJ. GABAA receptors as targets for novel anxiolytic drugs. World J Biol Psychiatry 2006; 7(4)231–237
   PubMed Web of Science ®Google Scholar
• Soyka M, Apelt SM, Lieb M, Wittchen HU. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. J Clin Psychopharmacol 2006; 26(6)657–660
   PubMed Web of Science ®Google Scholar
• Stenbacka M, Beck O, Leifman A, Romelsjö A, Helander A. Problem drinking in relation to treatment outcome among opiate addicts in maintenance treatment. Alcohol Rev 2007; 26(1)55–63
   PubMed Web of Science ®Google Scholar
• Strain EC, Brooner RK, Bigelow GE. Clustering of multiple substance use and psychiatric diagnosis in opioid addicts. Drug Alcohol Depend 1991; 27: 127–134
   PubMed Web of Science ®Google Scholar
• Teplin D, O'Connell T, Daiter J, Varenbut M. A psychometric study of the prevalence of DSM-IV personality disorders among office-based methadone maintenance patients. Am J Drug Alcohol Abuse 2004; 30(3)515–524
   PubMed Web of Science ®Google Scholar
• Van Limbeek J, Wouters L, Kaplan CD, Geerlings PJ, Alem V. International perspective – prevalence of psychopathology in drug-addicted Dutch. J Substance Abuse Treat 1992; 9: 43–52
   PubMedGoogle Scholar
• Verthein U, Degkwitz P, Kühne A, Krausz M. Beiträge aus der Wissenschaft – Komorbidität von Opiatabhängigkeit und psychischen Störungen – Ergebnisse einer Verlaufsuntersuchung. Sucht 1998; 44(4)232–246
   Google Scholar
• Villafranca SW, McKellar JD, Trafton JA, Humphreys K. Predictors of retention in methadone programs: a signal detection analysis. Drug Alcohol Depend 2006; 83(3)218–224
   PubMed Web of Science ®Google Scholar
• WHO (World Health Organisation). 1993. Internationale Klassifikation psychischer Störungen: ICD-10, Kapitel V (F); klinisch-diagnostische Leitlinien, 2. Auflage. Bern, Göttingen, Toronto, Seattle, WHO
   Google Scholar
• Wittchen HU, Essau CA, von Zerssen D, Krieg JC, Zaudig M. Lifetime and six-month prevalence of mental disorders in the Munich follow-up study. Eur Arch Psychiatry Clin Neurosci 1992; 241: 247–258
   PubMed Web of Science ®Google Scholar
• Wittchen, HU, Wunderlich, U, Gruschwitz, S, Zaudig, M. 1997. SKID-I Strukturiertes Klinisches Interview für DSM-IV, Achse I: Psychische Störungen. Göttingen: Hogrefe.
   Google Scholar
• Woody GE, McLellan AT, O'Brien CP, Luborsky L. Addressing psychiatric comorbidity. NIDA Res Monogr 1991; 106: 152–166
   PubMedGoogle Scholar